San Diego, CA — Accumetrics, Inc. announces that it has reached the halfway mark (1,600 patients) in the enrollment of its landmark clinical trial, GRAVITAS (Gauging Responsiveness with A VerifyNow® Assay Impact on Thrombosis And Safety).
ROCKVILLE, MD. — MacroGenics, Inc. announced today that Mr. Paulo F. Costa has been elected to the company’s Board as an independent director. Mr. Costa is the former President and Chief Executive Officer of Novartis U.S. Corporation. With more than 35 years of experience in operations and commercialization in the pharmaceutical industry, Mr. Costa brings valuable expertise to the MacroGenics Board.
Technological Leap to Sub-Millimeter Accuracy May Open New Doors for Treatment of Fast Moving Lung Cancer Tumors
SEATTLE, WA—Calypso Medical Technologies, Inc. today announced the publication of three new studies investigating the role of theCalypso® 4D Localization System in guiding immediate adjustments to radiation delivery in response to tumor motion, a concept known as real-time adaptive radiation treatment.
Phase 3 PROTÉGÉ ENCORE Clinical Trial Initiated
ROCKVILLE, MD and INDIANAPOLIS, IN – MacroGenics, Inc. and Eli Lilly and Company (NYSE:LLY) today announced that the PROTÉGÉ trial achieved its targeted patient enrollment. The trial is a pivotal Phase 2/3 clinical study evaluating teplizumab, an investigational compound under development for the treatment of individuals with recent-onset type 1 diabetes.
SAN DIEGO, CA – Accumetrics, Inc. announces today an exclusive distribution agreement with ELITech UK Limited for distribution of the VerifyNow System in the United Kingdom. The distribution agreement marks the beginning of several new distribution channels for the Company as it expands its reach both in scope and geography. ELITech UK will concentrate its efforts on reaching customers in surgery suites and catheterization labs within UK hospitals and other medical centers.
SEATTLE, WA–Calypso® Medical Technologies, Inc., a medical device company dedicated to shaping the future of radiation therapy delivery and management, today announced that First Coast Service Options, the Medicare Administrative Contractor for Florida, Puerto Rico and the U.S. Virgin Islands, assigned region-wide payment amounts to the CPT® code 0197T for intrafraction tracking to capture daily use of the Calypso® 4D Localization SystemTM.
Novel Stent Platform Designed for Radial Strength, Flexibility
HOUSTON, TX–IDEV Technologies, Incorporated, (IDEV) an emerging leader in the development and marketing of minimally invasive technologies, announced today that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for a multi-center clinical trial of its SUPERA stent, a novel stent platform designed for the treatment of peripheral artery disease (PAD) in the superficial femoral artery (SFA).
LENEXA, KS – CyDex Pharmaceuticals, Inc. today announced the presentation of Phase 2 clinical trial results of its novel, proprietary Captisol-Enabled® budesonide/azelastine nasal spray (CDX-313) for seasonal allergic rhinitis (SAR). The budesonide/azelastine combination nasal spray demonstrated statistically significant improved results over a nasal spray placebo.
Most Recent Indication Expands Treatment Platform to Allow Axxent® System to Deliver Surface Brachytherapy, Including Intraoperative Radiation Therapy (IORT)
SUNNYVALE, CA – Xoft, Inc., today announced that it has received clearance from the U.S. Food & Drug Administration (FDA) for a skin and surface treatment applicator for use with the Axxent® Electronic Brachytherapy (eBx) System to deliver surface brachytherapy, including Intraoperative Radiation Therapy (IORT).
SAN DIEGO, CA — Accumetrics, Inc. announced today that the Company has appointed Gregory J. Tibbitts, CPA to the position of Chief Financial Officer.
“We believe Greg’s extensive experience in both private and public companies will help Accumetrics to advance our financial operations and bring continued success to the Company,” says Timothy I. Still, Chief Executive Officer at Accumetrics.
PORTSMOUTH, NH — As part of its ongoing effort to improve patient outcomes for spinal procedures and reduce non-routine patient discharges for its hospital customers, Salient Surgical Technologies, Inc. today unveiled the AquamantysTM Epidural Vein Sealer (EVS) bipolar device at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in Las Vegas, NV.